311 related articles for article (PubMed ID: 28786523)
1. The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes.
Brønden A; Albér A; Rohde U; Gasbjerg LS; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2018 Feb; 20(2):362-369. PubMed ID: 28786523
[TBL] [Abstract][Full Text] [Related]
2. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer.
Brønden A; Mikkelsen K; Sonne DP; Hansen M; Våben C; Gabe MN; Rosenkilde M; Tremaroli V; Wu H; Bäckhed F; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2018 Jul; 20(7):1623-1631. PubMed ID: 29493868
[TBL] [Abstract][Full Text] [Related]
3. Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes.
Brønden A; Albér A; Rohde U; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2017 Nov; 102(11):4153-4162. PubMed ID: 28938439
[TBL] [Abstract][Full Text] [Related]
4. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
Hansen M; Scheltema MJ; Sonne DP; Hansen JS; Sperling M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2016 Jun; 18(6):571-80. PubMed ID: 26888164
[TBL] [Abstract][Full Text] [Related]
5. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Rohde U
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses.
Rohde U; Sonne DP; Christensen M; Hansen M; Brønden A; Toräng S; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2016 May; 101(5):2076-83. PubMed ID: 27003305
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer.
Nerild HH; Brønden A; Haddouchi AE; Ellegaard AM; Hartmann B; Rehfeld JF; Holst JJ; Sonne DP; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2024 Apr; 26(4):1252-1263. PubMed ID: 38151760
[TBL] [Abstract][Full Text] [Related]
8. Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review.
Kårhus ML; Brønden A; Sonne DP; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2017 Sep; 19(9):1214-1222. PubMed ID: 28304141
[TBL] [Abstract][Full Text] [Related]
9. New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs.
Gether IM; Nexøe-Larsen C; Knop FK
J Clin Endocrinol Metab; 2019 Jul; 104(7):2463-2472. PubMed ID: 30137354
[TBL] [Abstract][Full Text] [Related]
10. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.
Sonne DP; Hare KJ; Martens P; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G413-9. PubMed ID: 23275610
[TBL] [Abstract][Full Text] [Related]
11. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
12. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
[TBL] [Abstract][Full Text] [Related]
13. Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.
Xie C; Iroga P; Bound MJ; Grivell J; Huang W; Jones KL; Horowitz M; Rayner CK; Wu T
Diabetologia; 2024 Jul; 67(7):1260-1270. PubMed ID: 38561463
[TBL] [Abstract][Full Text] [Related]
14. Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling.
Gether IM; Bahne E; Nerild HH; Rehfeld JF; Hartmann B; Holst JJ; Vilsbøll T; Sonne DP; Knop FK
Eur J Endocrinol; 2024 Mar; 190(4):314-326. PubMed ID: 38551029
[TBL] [Abstract][Full Text] [Related]
15. Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.
Shaddinger BC; Young MA; Billiard J; Collins DA; Hussaini A; Nino A
J Clin Pharmacol; 2017 Oct; 57(10):1322-1329. PubMed ID: 28543352
[TBL] [Abstract][Full Text] [Related]
16. Hyperglycemia potentiates the slowing of gastric emptying induced by exogenous GLP-1.
Plummer MP; Jones KL; Cousins CE; Trahair LG; Meier JJ; Chapman MJ; Horowitz M; Deane AM
Diabetes Care; 2015 Jun; 38(6):1123-9. PubMed ID: 25784665
[TBL] [Abstract][Full Text] [Related]
17. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
[TBL] [Abstract][Full Text] [Related]
18. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
Am J Clin Nutr; 2016 Jan; 103(1):66-70. PubMed ID: 26607942
[TBL] [Abstract][Full Text] [Related]
19. Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release.
Ullmer C; Alvarez Sanchez R; Sprecher U; Raab S; Mattei P; Dehmlow H; Sewing S; Iglesias A; Beauchamp J; Conde-Knape K
Br J Pharmacol; 2013 Jun; 169(3):671-84. PubMed ID: 23488746
[TBL] [Abstract][Full Text] [Related]
20. Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery.
Albaugh VL; Banan B; Antoun J; Xiong Y; Guo Y; Ping J; Alikhan M; Clements BA; Abumrad NN; Flynn CR
Gastroenterology; 2019 Mar; 156(4):1041-1051.e4. PubMed ID: 30445014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
